Long-Term β-galacto-oligosaccharides Supplementation Decreases the Development of Obesity and Insulin Resistance in Mice Fed a Western-Type Diet.

Autor: Mistry RH; Department of Pediatrics , University of Groningen, University Medical Center Groningen, Groningen, 9713GZ, The Netherlands., Liu F; Department of Pediatrics , University of Groningen, University Medical Center Groningen, Groningen, 9713GZ, The Netherlands.; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, 141 83, Sweden., Borewicz K; Laboratory of Microbiology, Wageningen University & Research, Wageningen, P.O. Box 8033, 6700 EH, The Netherlands., Lohuis MAM; Department of Pediatrics , University of Groningen, University Medical Center Groningen, Groningen, 9713GZ, The Netherlands., Smidt H; Laboratory of Microbiology, Wageningen University & Research, Wageningen, P.O. Box 8033, 6700 EH, The Netherlands., Verkade HJ; Department of Pediatrics , University of Groningen, University Medical Center Groningen, Groningen, 9713GZ, The Netherlands., Tietge UJF; Department of Pediatrics , University of Groningen, University Medical Center Groningen, Groningen, 9713GZ, The Netherlands.; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, 141 83, Sweden.; Clinical Chemistry, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, SE-141 86, Sweden.
Jazyk: angličtina
Zdroj: Molecular nutrition & food research [Mol Nutr Food Res] 2020 Jun; Vol. 64 (12), pp. e1900922. Date of Electronic Publication: 2020 May 25.
DOI: 10.1002/mnfr.201900922
Abstrakt: Scope: The gut microbiota might critically modify metabolic disease development. Dietary fibers such as galacto-oligosaccharides (GOS) presumably stimulate bacteria beneficial for metabolic health. This study assesses the impact of GOS on obesity, glucose, and lipid metabolism.
Methods and Results: Following Western-type diet feeding (C57BL/6 mice) with or without β-GOS (7% w/w, 15 weeks), body composition, glucose and insulin tolerance, lipid profiles, fat kinetics and microbiota composition are analyzed. GOS reduces body weight gain (p < 0.01), accumulation of epididymal (p < 0.05), perirenal (p < 0.01) fat, and insulin resistance (p < 0.01). GOS-fed mice have lower plasma cholesterol (p < 0.05), mainly within low-density lipoproteins, lower intestinal fat absorption (p < 0.01), more fecal neutral sterol excretion (p < 0.05) and higher intestinal GLP-1 expression (p < 0.01). Fecal bile acid excretion is lower (p < 0.01) in GOS-fed mice with significant compositional differences, namely decreased cholic, α-muricholic, and deoxycholic acid excretion, whereas hyodeoxycholic acid increased. Substantial changes in microbiota composition, conceivably beneficial for metabolic health, occurred upon GOS feeding.
Conclusion: GOS supplementation to a Western-type diet improves body weight gain, dyslipidemia, and insulin sensitivity, supporting a therapeutic potential of GOS for individuals at risk of developing metabolic syndrome.
(© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
Databáze: MEDLINE
Externí odkaz: